Lomitapide Mesylate Global Patent Coverage & Expiry Overview

Track protection status across key markets to assess launch feasibility.

Start your free 7-Day Trial! Book a demo to explore our global patent data.

It is formulated by 1 pharmaceutical company such as CHIESI. It is marketed under 1 brand name, including JUXTAPID. Available in 6 different strengths, such as EQ 5MG BASE, EQ 10MG BASE, EQ 20MG BASE and others, and administered through 1 route including CAPSULE;ORAL.

Strategic Dashboard

info

insightsStrategic Insights

Sourcing & Feasibility

check_circle API availability: autorenew Loading API feasibility...

groups Licensing: 1 potential partners

calendar_todayUS Launch window: autorenew Loading launch window...

timeline Key Patent Barrier & Expiry Timeline

autorenew Loading patent barriers...

factoryGeneric Manufacturer Snapshot

autorenew Loading manufacturers...

gavelRisk & Opportunity Summary

dangerous Risk: autorenew Loading risk analysis...
watch_later Watch: autorenew Loading watch analysis...
rocket_launch Opportunity: autorenew Loading opportunity analysis...
flag
gavel
calendar_today
calendar_today

Access Global Patent Data

Stay ahead with worldwide patent expiry and latest updates.

Comprehensive global patent expiry timelines
Full patent family details and status updates

Orange Book Drug Approval Timeline

FDA approval history for this ingredient

NDA (New Drug Application) ANDA (Generic Application)

Access Global Exclusivity and Patent Expiry Extensions

Stay ahead with worldwide patent expiry insights, exclusivity data, and latest updates.

Comprehensive global patent expiry timelines
Full patent family details and status updates
Latest exclusivity data and extensions

US Orange Book Patents Expiration Timeline

Key expiration dates for US patents covering this ingredient

View Global Patents Expiration Timeline

Stay ahead with worldwide patent expiry insights, market data, and research updates.

Comprehensive global patent expiry timelines
Full patent family details and status updates

Orange Book Drug Strengths

Latest drug strengths approved by FDA

Strength Route of Administration Companies Latest Approval Date

Orange Book Patents

Patents approved by the FDA for the ingredient

Patent Number Publication Date Legal Status Patent Expiry Date
{"application_id":"48650","ingredient":"LOMITAPIDE MESYLATE","trade_name":"JUXTAPID","family_id":"a2a4555a5ba84d2a9547","publication_number":"US9861622B2","cleaned_patent_number":"9861622","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-07","publication_date":"2018-01-09","legal_status":"Granted"} US9861622B2 09 Jan, 2018 Granted 07 Mar, 2025
{"application_id":"48652","ingredient":"LOMITAPIDE MESYLATE","trade_name":"JUXTAPID","family_id":"a2a4555a5ba84d2a9547","publication_number":"US10555938B2","cleaned_patent_number":"10555938","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-07","publication_date":"2020-02-11","legal_status":"Expired"} US10555938B2 11 Feb, 2020 Expired 07 Mar, 2025
{"application_id":"48651","ingredient":"LOMITAPIDE MESYLATE","trade_name":"JUXTAPID","family_id":"a2a4555a5ba84d2a9547","publication_number":"US10016404B2","cleaned_patent_number":"10016404","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-07","publication_date":"2018-07-10","legal_status":"Expired"} US10016404B2 10 Jul, 2018 Expired 07 Mar, 2025
{"application_id":"48621","ingredient":"LOMITAPIDE MESYLATE","trade_name":"JUXTAPID","family_id":"a2a4555a5ba84d2a9547","publication_number":"US8618135B2","cleaned_patent_number":"8618135","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-07","publication_date":"2013-12-31","legal_status":"Granted"} US8618135B2 31 Dec, 2013 Granted 07 Mar, 2025
{"application_id":"48647","ingredient":"LOMITAPIDE MESYLATE","trade_name":"JUXTAPID","family_id":"a2a4555a5ba84d2a9547","publication_number":"US9265758B2","cleaned_patent_number":"9265758","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-07","publication_date":"2016-02-23","legal_status":"Granted"} US9265758B2 23 Feb, 2016 Granted 07 Mar, 2025
{"application_id":"48648","ingredient":"LOMITAPIDE MESYLATE","trade_name":"JUXTAPID","family_id":"a2a4555a5ba84d2a9547","publication_number":"US9364470B2","cleaned_patent_number":"9364470","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-07","publication_date":"2016-06-14","legal_status":"Granted"} US9364470B2 14 Jun, 2016 Granted 07 Mar, 2025
{"application_id":"48658","ingredient":"LOMITAPIDE MESYLATE","trade_name":"JUXTAPID","family_id":"","publication_number":"US9433617B2","cleaned_patent_number":"9433617","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2025-03-07","publication_date":"2016-09-06","legal_status":"Granted"} US9433617B2 06 Sep, 2016 Granted 07 Mar, 2025
{"application_id":"48646","ingredient":"LOMITAPIDE MESYLATE","trade_name":"JUXTAPID","family_id":"a2a4555a5ba84d2a9547","publication_number":"US7932268B2","cleaned_patent_number":"7932268","drug_product_flag":"-","drug_substance_flag":"-","use_codes":["-"],"definitions":["-"],"patent_expire_date_text":"2027-08-19","publication_date":"2011-04-26","legal_status":"Granted"} US7932268B2 26 Apr, 2011 Granted 19 Aug, 2027

Recent Clinical Trials

Latest clinical trials and research studies for this ingredient

NCT ID Title Status Phase Conditions Start Date Completion Date

API Suppliers/Manufacturer (Branded/Generic companies)

Manufacturing Locations

View Complete Supplier List

Unlock access to all suppliers of Lomitapide Mesylate

Access a comprehensive list of global suppliers
Get information on each supplier

Note: Patent expirations and exclusivity timelines are dynamic and may shift based on litigation, regulatory extensions, and maintenance filings. Regular monitoring is advised.